Karmanos Genitourinary Team Leader Contributes To Article On Prostate Cancer In New England Journal Of Medicine
All patients on the trial had a form of prostate cancer that is referred to as 'castrate-resistant,' a stage of prostate cancer when the traditional testosterone suppression treatment is no longer effective against the cancer.
Dr. Vaishampayan noted that all men who are diagnosed with metastatic, hormone-sensitive prostate cancer on androgen deprivation become castrate-resistant within a median of 18-24 months after their initial diagnosis. The study established parameters for assessing the risk factors of early onset castrate-resistant disease, she said.
"The information that complete androgen deprivation and intermittent androgen deprivation have different survival outcomes should be an important factor during patient and physician discussions and decisions regarding the risks and benefits of androgen-deprivation therapy," Dr. Vaishampayan said. "This national trial addressed an important question and involved tremendous effort, patients and collaboration.
"I am proud to represent a fine institution like Karmanos Cancer Center, which is committed to clinical research for improving outcomes in patients with prostate cancer," she added. "I am indebted to the patients who enrolled in this trial and, in turn, helped countless others afflicted with the disease. Karmanos' clinical trials staff also was very dedicated to the cause and worked tirelessly to help us achieve our goals."About the Barbara Ann Karmanos Cancer Institute Located in mid-town Detroit, Michigan, the Barbara Ann Karmanos Cancer Institute is one of 41 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for nearly 6,000 new patients annually on a budget of $265 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, Karmanos is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 physicians and researchers on faculty at the Wayne State University School of Medicine, and supported by thousands of volunteer and financial donors, Karmanos strives to prevent, detect and eradicate all forms of cancer. Its long-term partnership with the WSU School of Medicine enhances the collaboration of critical research and academics related to cancer care. Gerold Bepler, M.D., Ph.D., is the Institute's president and chief executive officer. For more information call 1-800-KARMANOS or go to www.karmanos.org . SOURCE Karmanos Cancer Institute
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV